Condition: Cancer · Immune System Disorder · Inflammatory Reaction · Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in different organs, commonly called immune-related adverse events (irAEs). irAEs can lead to treatment discontinuation, or can be life-threatening in extreme cases. The causes of irAEs are largely unknown and there are no reliable predictive biomarkers. The Montreal Immune-Related Adverse Events (MIRAE) study collects clinical information and biospecimens (blood, tissue, stool) from cancer patients treated with ICI to facilitate research on the identification of predictive biomarkers of irAEs, their causes, and the design of effective management strategies.
This description comes directly from the study's public registry record.
Marie Hudson, MD · 1-514-340-8222 · marie.hudson@mcgill.ca, marie.hudson.med@ssss.gouv.qc.ca
Manuel Flores, PhD · 1-514-677-8155 · Manuel.Flores.Molina.ccomtl@ssss.gouv.qc.ca
Always discuss trial participation with your own doctor first.
| Jewish General Hospital | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05139706